Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeticholic Acid for Prevention in Barrett's Esophagus
NCT04939051Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jan 2024
- Primary completion
- Sep 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised trial in Barrett's esophagus comparing Arm I (OCA) with Arm II (placebo) (2 arms). Primary endpoint: Mean change in leucine-rich repeat-containing G-protein coupled receptor 5+ cell count at 6 months. Started Jan 2024; status: recruiting.
02
Drugs
obeticholic acid
03
Conditions
Barrett's esophagus
Beyond the preview
Go deeper on NCT04939051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04939051.